University of Alabama at Birmingham to Enroll Patients in Pilot Study Using Mytrus and its iPad Application - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
University of Alabama at Birmingham to Enroll Patients in Pilot Study Using Mytrus and its iPad Application

Source: Company News Release

Mytrus, an innovative clinical technology and services company for medical and pharmaceutical research, today announced that the University of Alabama at Birmingham (UAB) will use its iPad® application in an upcoming pilot study supported by the U.S. Department of Health & Human Services Agency for Healthcare Research and Quality. UAB is evaluating how digital tools might simplify enrollment and enhance patient understanding during the informed consent process. Kenneth G. Saag, MD, Msc, professor in the UAB Department of Medicine, will lead the study.

For more specific information on UAB’s usage of the Mytrus iPad application, read UAB’s article, “UAB studying high tech way to secure informed consent in research trials” by Bob Shepard, published earlier this month.

Using animation and other visual imagery, the Mytrus iPad application is the first in the industry to condense the complex and critical disclosure information required at the start of a clinical trial into an easy-to-understand, digitized format. This new approach not only helps patients better understand the clinical trial process; it helps researchers gain valuable insight into the speed and effectiveness of the informed consent process in multi-center studies.

“The Mytrus application gives study sponsors a window into the informed consent process that they’ve never had before,” said Anthony Costello, CEO of Mytrus. “Like many sponsors we work with, the University of Alabama at Birmingham also recognizes that increasing a patient’s understanding and comfort level during consent is the best way to retain highly motivated and protocol compliant patients throughout the study.”

Related Links:

An Idea Whose Time Came

Greenphire and Mytrus Partner to Provide Web-based Solutions for Patient Recruitment and Retention

 

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Company News Release,
Click here